Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA: 688076)
China
· Delayed Price · Currency is CNY 61.65
-0.79 (-1.27%)
Oct 10, 2024, 3:00 PM CST
Jiangsu Sinopep-Allsino Biopharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 1,463 | 1,033 | 648.03 | 641.71 | 564.99 | 370.78 | Upgrade
|
| Other Revenue | 1.29 | 0.82 | 3.26 | 2.16 | 1.89 | 0.75 | Upgrade
|
| Revenue | 1,464 | 1,034 | 651.29 | 643.87 | 566.87 | 371.53 | Upgrade
|
| Revenue Growth (YoY) | 86.82% | 58.69% | 1.15% | 13.58% | 52.58% | 45.40% | Upgrade
|
| Cost of Revenue | 544.5 | 444.27 | 307.94 | 306.3 | 249.55 | 179.93 | Upgrade
|
| Gross Profit | 919.77 | 589.28 | 343.36 | 337.57 | 317.32 | 191.6 | Upgrade
|
| Selling, General & Admin | 306.29 | 268.23 | 186.98 | 150.49 | 120 | 86.93 | Upgrade
|
| Research & Development | 196.39 | 124.89 | 69.47 | 63.09 | 60.53 | 47.74 | Upgrade
|
| Other Operating Expenses | 3.79 | 0.02 | 9.25 | 5.24 | 3.65 | 3.16 | Upgrade
|
| Operating Expenses | 524.15 | 398.25 | 271.58 | 220.47 | 185.87 | 139.69 | Upgrade
|
| Operating Income | 395.62 | 191.04 | 71.78 | 117.1 | 131.45 | 51.92 | Upgrade
|
| Interest Expense | -22.93 | -16.09 | -9.26 | -6.12 | -11.63 | -7.16 | Upgrade
|
| Interest & Investment Income | 7.48 | 9.11 | 28.54 | 8.38 | 7.16 | 1.03 | Upgrade
|
| Currency Exchange Gain (Loss) | 4.8 | -1.38 | 1.03 | -1.58 | -7.73 | 1.64 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.19 | -0.47 | -0.3 | -0 | -1.12 | -0.68 | Upgrade
|
| EBT Excluding Unusual Items | 385.17 | 182.22 | 91.79 | 117.78 | 118.14 | 46.74 | Upgrade
|
| Impairment of Goodwill | - | - | - | -1.28 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.57 | 0.26 | -1.96 | 0.13 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -11.42 | -15.06 | 18.44 | -0.97 | -4.12 | -0.31 | Upgrade
|
| Asset Writedown | - | - | - | - | - | -0.67 | Upgrade
|
| Other Unusual Items | 9.04 | 5.71 | 14.9 | 10.07 | 32.55 | 7.64 | Upgrade
|
| Pretax Income | 382.21 | 173.13 | 123.16 | 125.73 | 146.56 | 53.41 | Upgrade
|
| Income Tax Expense | 24.85 | 7.67 | 0.39 | 16.92 | 26.53 | 8.61 | Upgrade
|
| Earnings From Continuing Operations | 357.37 | 165.45 | 122.77 | 108.81 | 120.03 | 44.81 | Upgrade
|
| Minority Interest in Earnings | -9.12 | -2.52 | 6.34 | 6.58 | 3.41 | 3.8 | Upgrade
|
| Net Income | 348.25 | 162.94 | 129.11 | 115.39 | 123.44 | 48.61 | Upgrade
|
| Net Income to Common | 348.25 | 162.94 | 129.11 | 115.39 | 123.44 | 48.61 | Upgrade
|
| Net Income Growth | 155.83% | 26.20% | 11.89% | -6.52% | 153.94% | 10.71% | Upgrade
|
| Shares Outstanding (Basic) | 217 | 214 | 212 | 192 | 160 | 162 | Upgrade
|
| Shares Outstanding (Diluted) | 222 | 214 | 212 | 192 | 160 | 162 | Upgrade
|
| Shares Change (YoY) | 7.13% | 1.29% | 10.05% | 19.96% | -1.06% | 18.09% | Upgrade
|
| EPS (Basic) | 1.61 | 0.76 | 0.61 | 0.60 | 0.77 | 0.30 | Upgrade
|
| EPS (Diluted) | 1.57 | 0.76 | 0.61 | 0.60 | 0.77 | 0.30 | Upgrade
|
| EPS Growth | 138.80% | 24.59% | 1.67% | -22.08% | 156.67% | -6.25% | Upgrade
|
| Free Cash Flow | -365.43 | -310.43 | -409.07 | -52.61 | 30.1 | -230.25 | Upgrade
|
| Free Cash Flow Per Share | -1.64 | -1.45 | -1.93 | -0.27 | 0.19 | -1.42 | Upgrade
|
| Dividend Per Share | 0.500 | 0.400 | 0.200 | 0.150 | - | - | Upgrade
|
| Dividend Growth | 150.00% | 100.00% | 33.33% | - | - | - | Upgrade
|
| Gross Margin | 62.81% | 57.02% | 52.72% | 52.43% | 55.98% | 51.57% | Upgrade
|
| Operating Margin | 27.02% | 18.48% | 11.02% | 18.19% | 23.19% | 13.97% | Upgrade
|
| Profit Margin | 23.78% | 15.76% | 19.82% | 17.92% | 21.78% | 13.08% | Upgrade
|
| Free Cash Flow Margin | -24.96% | -30.03% | -62.81% | -8.17% | 5.31% | -61.97% | Upgrade
|
| EBITDA | 557.35 | 322.43 | 170.52 | 198.73 | 202.16 | 93.54 | Upgrade
|
| EBITDA Margin | 38.06% | 31.20% | 26.18% | 30.87% | 35.66% | 25.18% | Upgrade
|
| D&A For EBITDA | 161.74 | 131.39 | 98.75 | 81.63 | 70.71 | 41.63 | Upgrade
|
| EBIT | 395.62 | 191.04 | 71.78 | 117.1 | 131.45 | 51.92 | Upgrade
|
| EBIT Margin | 27.02% | 18.48% | 11.02% | 18.19% | 23.19% | 13.97% | Upgrade
|
| Effective Tax Rate | 6.50% | 4.43% | 0.31% | 13.46% | 18.10% | 16.11% | Upgrade
|
| Revenue as Reported | 1,464 | 1,034 | 651.29 | 643.87 | 566.87 | 371.53 | Upgrade
|
| Advertising Expenses | - | - | - | - | - | 0.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.